Aclaris Therapeutics (ACRS) Shares Outstanding (Weighted Average) (2017 - 2025)
Aclaris Therapeutics (ACRS) has 9 years of Shares Outstanding (Weighted Average) data on record, last reported at $122.6 million in Q4 2025.
- For Q4 2025, Shares Outstanding (Weighted Average) rose 58.56% year-over-year to $122.6 million; the TTM value through Dec 2025 reached $122.6 million, up 58.56%, while the annual FY2025 figure was $122.6 million, 58.56% up from the prior year.
- Shares Outstanding (Weighted Average) reached $122.6 million in Q4 2025 per ACRS's latest filing, roughly flat from $122.6 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $122.6 million in Q3 2025 and bottomed at $50.3 million in Q1 2021.
- Average Shares Outstanding (Weighted Average) over 5 years is $76.6 million, with a median of $69.6 million recorded in 2023.
- Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.78% in 2024, then skyrocketed 72.2% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $56.7 million in 2021, then grew by 14.95% to $65.2 million in 2022, then increased by 7.05% to $69.8 million in 2023, then increased by 10.73% to $77.3 million in 2024, then surged by 58.56% to $122.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $122.6 million in Q4 2025, $122.6 million in Q3 2025, and $122.5 million in Q2 2025.